· High blood pressure.

· Prophylaxis of stress angina attacks.

· Long-term treatment after myocardial infarction (acebutolol decreases the risk of recurrence, myocardial infarction and mortality, particularly sudden death). >
· Treatment of certain rhythm disorders: supraventricular (tachycardia, flutters and atrial fibrillations, tachycardia, junctional) or ventricular (ventricular extrasystolia, ventricular tachycardias). >
· Hypertension: The usual daily dose of acebutolol is 400 mg, which is administered either preferably in one dose, taken every morning (there is a dosage form of 400 mg), or in two divided doses , One in the morning and one in the evening This dose may be increased in case of severe hypertension

· Prophylaxis of stress angina attacks, tachyarrhythmias: The daily dose may range from 400 to 800 mg (600 mg on average), starting with the lowest dose and adapting, in incremental steps, the Dosage in the clinical or electrocardiogram state

· Long-term treatment after myocardial infarction: treatment with acebutolol should preferably be instituted between the 3 rd and the 21 st day after the acute episode of infarction: the dosage is 2 tablets per day, in two doses.

Film-coated tablet


(C07AB04: system, cardiovascular)

Acebutolol is characterized by three pharmacological properties

· Beta-blocking beta-1 activity, selective

· Antiarrhythmic effect

· Partial agonist potency (sympathomimetic activity, intrinsic moderate).

Not applicable.

This medicinal product MUST NEVER be used in the following cases

· Asthma and chronic obstructive pulmonary disease in their severe forms

· Cardiac insufficiency not controlled by the treatment.

· Cardiogenic shock.

· Atrioventricular blocks of the second and third degrees, not paired.

· Prinzmetal Angina (in pure and monotherapy forms).

· Sinus disease (including sino-atrial block).

· Bradycardia (


In the case of treatment with acebutolol, breast-feeding is contraindicated due to a significant passage of milk (see section on pharmacokinetic properties).

At the clinical level

The most frequently reported

· Asthenia

· Cooling the ends

· Bradycardia, severe if necessary

· Digestive disorders (gastralgia, nausea, vomiting)

· Impotence.

Much more rarely

· Deceleration of atrioventricular conduction or intensification of an existing atrioventricular block

· Heart failure

· Blood pressure drop

· Bronchospasm

· Hypoglycemia

· Raynaud's syndrome

· Aggravation of an existing intermittent claudication

· Various skin manifestations including rashes, psoriasiformes, or exacerbation of psoriasis (see Warnings and Precautions for Use)


· Pneumopathies of immuno-allergic origin.

Biologically speaking

In rare cases, the appearance of antinuclear antibodies accompanied only by exceptional clinical manifestations in the form of lupus syndrome and which led to discontinuation of treatment.

· Prophylaxis of stress angina attacks · Long-term treatment after myocardial infarction (acebutolol decreases the risk of recurrence, myocardial infarction and mortality, especially (Tachycardia, flutters and atrial fibrillation, tachycardia, junctional) or ventricular (ventricular extrasystolia, ventricular tachycardia).